What is claimed is:

1. A compound of formula (I):



(I)

wherein W is hydrogen, C_{1-10} alkyl, C_{3-12} cycloalkyl, C_{3-12} cycloalkylC_{1-4}alkyl-, C_{1-10} alkoxy, C_{3-12} cycloalkoxy-, C_{1-10} alkyl substituted with 1-3 halogen, C_{3-12} cycloalkyl substituted with 1-3 halogen, C_{3-12} cycloalkylC_{1-4}alkyl- substituted with 1-3 halogen, C_{1-10} alkoxy substituted with 1-3 halogen, C_{3-12} cycloalkoxy- substituted with 1-3 halogen, $-COOV_1$, $-C_{1-4}COOV_1$, $-CH_2OH$, $-SO_2N(V_1)_2$, hydroxyC_{1-10}alkyl-, hydroxyC_{3-10}cycloalkyl-, cyanoC_{1-10}alkyl-, cyanoC_{3-10}cycloalkyl-, $-CON(V_1)_2$, $NH_2SO_2C_{1-4}$alkyl-, NH_2SOC_{1-4}alkyl-, sulfonylaminoC_{1-10}alkyl-, diaminoalkyl-, -sulfonylC_{1-4}alkyl, a 6-membered heterocyclic ring, a 6-membered heteroaromatic ring, a 6-membered heterocyclicC_{1-4}alkyl-, a 6-membered heteroaromaticC_{1-4}alkyl-, a 6-membered aromatic ring, a 6-membered aromaticC_{1-4} alkyl-, a 5-membered heterocyclic ring optionally substituted with an oxo or thio, a 5-membered heteroaromatic ring, a 5-membered heterocyclicC_{1-4}alkyl- optionally substituted with an oxo or thio, a 5-membered heteroaromaticC_{1-4}alkyl-, $-C_{1-5}(=O)W_1$, $-C_{1-5}(=NH)W_1$, $-C_{1-5}NHC(=O)W_1$, $-C_{1-5}NHS(=O)_2W_1$, $-C_{1-5}NHS(=O)W_1$, wherein W_1 is hydrogen, C_{1-10} alkyl, C_{3-12} cycloalkyl, C_{1-10} alkoxy, C_{3-12} cycloalkoxy, $-CH_2OH$, amino, C_{1-4}alkylamino-, diC_{1-4}alkylamino-, or a 5-membered heteroaromatic ring optionally substituted with 1-3 lower alkyl;

wherein each V_1 is independently selected from H, C_{1-6} alkyl, C_{3-6} cycloalkyl, benzyl or phenyl

Q is a C_{1-8} alkyl, 5-8 membered cycloalkyl, 5-8 membered heterocyclic or a 6 membered aromatic or heteroaromatic group;

n is an integer from 0 to 3;

A, B and C are independently hydrogen, C_{1-10} alkyl, C_{3-12} cycloalkyl, C_{1-10} alkoxy, C_{3-12} cycloalkoxy, $-CH_2OH$, $-NHSO_2$, hydroxyC_{1-10}alkyl-, aminocarbonyl-, C_{1-4}alkylaminocarbonyl-, diC_{1-4}alkylaminocarbonyl-, acylamino-, acylaminoalkyl-, amide, sulfonylaminoC_{1-10}alkyl-, or A-B can together form a C_{2-6} bridge, or B-C can together form a C_{3-7} bridge, or A-C can together form a C_{1-5} bridge;

Z is selected from the group consisting of a bond, straight or branched C_{1-6} alkylene, -NH-, $-CH_2O-$, $-CH_2NH-$, $-CH_2N(CH_3)-$, $-NHCH_2-$, $-CH_2CONH-$, $-NHCH_2CO-$, $-CH_2CO-$, $-COCH_2-$, $-CH_2COCH_2-$, $-CH(CH_3)-$, -CH=, -O- and -HC=CH-, wherein the carbon and/or nitrogen atoms are unsubstituted or substituted with one or more lower alkyl, hydroxy, halo or alkoxy group;

R_1 is selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{3-12}cycloalkyl, C_{2-10}alkenyl, amino, C_{1-10}alkylamino-, C_{3-12}cycloalkylamino-, $-COOV_1$, $-C_{1-4}COOV_1$, cyano, cyanoC_{1-10}alkyl-, cyanoC_{3-10}cycloalkyl-, NH_2SO_2-, $NH_2SO_2C_{1-4}$alkyl-, NH_2SOC_{1-4}alkyl-, aminocarbonyl-, C_{1-4}alkylaminocarbonyl-, diC_{1-4}alkylaminocarbonyl-, benzyl, C_{3-12} cycloalkenyl-, a monocyclic, bicyclic or tricyclic aryl or heteroaryl ring, a hetero-monocyclic ring, a hetero-bicyclic ring system, and a spiro ring system of the formula (II):



(II)

wherein X_1 and X_2 are independently selected from the group consisting of NH, O, S

and CH_2; and wherein said alkyl, cycloalkyl, alkenyl, C_{1-10}alkylamino-, C_{3-12}cycloalkylamino-, or benzyl of R_1 is optionally substituted with 1-3 substituents selected from the group consisting of halogen, hydroxy, C_{1-10} alkyl, C_{1-10} alkoxy, nitro, trifluoromethyl-, cyano, -$COOV_1$, -$C_{1-4}COOV_1$, cyanoC_{1-10}alkyl-, -$C_{1-5}(=O)W_1$, -$C_{1-5}NHS(=O)_2W_1$, -$C_{1-5}NHS(=O)W_1$, a 5-membered heteroaromaticC_{0-4}alkyl-, phenyl, benzyl, benzyloxy, said phenyl, benzyl, and benzyloxy optionally being substituted with 1-3 substituents selected from the group consisting of halogen, C_{1-10} alkyl-, C_{1-10} alkoxy-, and cyano; and wherein said C_{3-12} cycloalkyl, C_{3-12} cycloalkenyl, monocyclic, bicyclic or tricyclic aryl, heteroaryl ring, hetero-monocyclic ring, hetero-bicyclic ring system, or spiro ring system of the formula (II) is optionally substituted with 1-3 substituents selected from the group consisting of halogen, C_{1-10} alkyl, C_{1-10} alkoxy, nitro, trifluoromethyl-, phenyl, benzyl, phenyloxy and benzyloxy, wherein said phenyl, benzyl, phenyloxy or benzyloxy is optionally substituted with 1-3 substituents selected from the group consisting of halogen, C_{1-10} alkyl, C_{1-10} alkoxy, and cyano;

R_2 is selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{3-12} cycloalkyl and halogen, said alkyl or cycloalkyl optionally substituted with an oxo, amino, alkylamino or dialkylamino group;

or a pharmaceutically acceptable salt thereof or solvate thereof.

2. A compound of claim 1, wherein Q is phenyl or a 6 membered heteroaromatic group containing 1-3 nitrogen atoms.

3. A compound of claim 1, wherein W is selected from the group consisting of -$CH_2C{=}ONH_2$, -$C(NH)NH_2$, pyridylmethyl, cyclopentyl, cyclohexyl, furanylmethyl, -$C{=}OCH_3$, -$CH_2CH_2NHC{=}OCH_3$, -SO_2CH_3, $CH_2CH_2NHSO_2CH_3$, furanylcarbonyl-, methylpyrrolylcarbonyl-, diazolecarbonyl-, azolemethyl-, trifluoroethyl-, hydroxyethyl-, cyanomethyl-, oxo-oxazolemethyl-, and diazolemethyl-.

4. A compound of claim 1, wherein ZR_1 is selected from the group consisting of cyclohexylethyl-, cyclohexylmethyl-, cyclopentylmethyl-, dimethylcyclohexylmethyl-, phenylethyl-, pyrrolyltrifluoroethyl-, thienyltrifluoroethyl-, pyridylethyl-, cyclopentyl-, cyclohexyl-, methoxycyclohexyl-, tetrahydropyranyl-, propylpiperidinyl-, indolylmethyl-, pyrazoylpentyl-, thiazolylethyl-, phenyltrifluoroethyl-, hydroxyhexyl-, methoxyhexyl-, isopropoxybutyl-, hexyl-, and oxocanylpropyl-.

5. A compound of claim 1, wherein at least one of ZR_1 or W is selected from the group consisting of CH_2COOV_1, tetrazolylmethyl-, cyanomethyl-, NH_2SO_2methyl-, NH_2SOmethyl-, aminocarbonylmethyl-, C_{1-4}alkylaminocarbonylmethyl-, and diC_{1-4}alkylaminocarbonylmethyl-.

6. A compound of claim 1, wherein ZR_1 is 3,3 diphenylpropyl optionally substituted at the 3 carbon of the propyl with $-COOV_1$, tetrazolylC_{0-4}alkyl-, cyano-, aminocarbonyl-, C_{1-4}alkylaminocarbonyl-, or diC_{1-4}alkylaminocarbonyl-.

7. A compound of formula (IA):



(IA)

wherein

n is an integer from 0 to 3;

Z is selected from the group consisting of a bond, $-CH_2-$, -NH-, $-CH_2O-$, $-CH_2CH_2-$, $-CH_2NH-$, $-CH_2N(CH_3)-$, $-NHCH_2-$, $-CH_2CONH-$, $-NHCH_2CO-$, $-CH_2CO-$, $-COCH_2-$, $-CH_2COCH_2-$, $-CH(CH_3)-$, -CH=, and -HC=CH-, wherein the carbon and/or nitrogen atoms are unsubstituted or substituted with a lower alkyl, halogen, hydroxy or alkoxy group;

R_1 is selected from the group consisting of hydrogen, C_{1-10}alkyl, C_{3-12}cycloalkyl, C_{2-10}alkenyl, amino, C_{1-10}alkylamino, C_{3-12}cycloalkylamino, benzyl, C_{3-12} cycloalkenyl, a monocyclic, bicyclic or tricyclic aryl or heteroaryl ring, a hetero-monocyclic ring, a hetero-bicyclic ring system, and a spiro ring system of the formula (II):



(II)

wherein X_1 and X_2 are independently selected from the group consisting of NH, O, S and CH_2;

wherein said alkyl, cycloalkyl, alkenyl, C_{1-10}alkylamino, C_{3-12}cycloalkylamino, or benzyl is optionally substituted with 1-3 substituents selected from the group consisting of halogen, C_{1-10} alkyl, C_{1-10} alkoxy, nitro, trifluoromethyl, cyano, phenyl, benzyl, benzyloxy, said phenyl, benzyl, and benzyloxy optionally being substituted with 1-3 substituents selected from the group consisting of halogen, C_{1-10} alkyl, C_{1-10} alkoxy, and cyano;

wherein said C_{3-12} cycloalkyl, C_{3-12} cycloalkenyl, monocyclic, bicyclic or tricyclic aryl, heteroaryl ring, hetero-monocyclic ring, hetero-bicyclic ring system, and spiro ring system of the formula (II) are optionally substituted with 1-3 substituents selected from the group consisting of halogen, C_{1-10} alkyl, C_{1-10} alkoxy, nitro, trifluoromethyl, phenyl, benzyl, phenyloxy and benzyloxy, wherein said phenyl, benzyl, phenyloxy and benzyloxy are optionally substituted with 1-3 substituents selected from the group consisting of halogen, C_{1-10} alkyl, C_{1-10} alkoxy, and cyano;

R_2 is selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{3-12} cycloalkyl and halogen, said alkyl optionally substituted with an oxo group;

or a pharmaceutically acceptable salt thereof.

8. A compound of claim 7, wherein R_1 is alkyl selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl and hexyl.

9. A compound of claim 7, wherein R_1 is cycloalkyl selected from the group consisting of cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, and norbornyl.

10. A compound of claim 7, wherein R_1 is tetrahydronaphthyl, decahydronaphthyl or

dibenzocycloheptyl.

11. A compound of claim 7, wherein R_1 is phenyl or benzyl.

12. A compound of claim 7, wherein R_1 is a bicyclic aromatic ring.

13. A compound of claim 12, wherein said bicyclic aromatic ring is indenyl, quinoline or naphthyl.

14. A compound of claim 7, wherein Z is a bond, methyl, or ethyl.

15. A compound of claim 7, wherein n is 0.

16. A compound of claim 7, wherein X_1 and X_2 are both O.

17. A compound selected from the group consisting of
8-(4-propylcyclohexyl)-1-phenyl-2,3,8-triazospiro[4.5]decan-4-one;
8-(5-methylhex-2-yl)-1-phenyl-2,3,8-triazospiro[4.5]decan-4-one;
8-norbornyl-1-phenyl-2,3,8-triazospiro[4.5]decan-4-one;
8-(decahydro-2-naphthyl)-1-phenyl-2,3,8-triazospiro[4.5]decan-4-one;
8-(cyclooctylmethyl)-1-phenyl-2,3,8-triazospiro[4.5]decan-4-one;
8-(1,2,3,4-tetrahydro-2-naphthyl)-1-phenyl-2,3,8-triazospiro[4.5]decan-4-one;
8-[4-(2-propyl)-cyclohexyl]-1-phenyl-2,3,8-triazospiro[4.5]decan-4-one;
8-(1,3-dihydroinden-2-yl)-1-phenyl-2,3,8-triazospiro[4.5]decan-4-one;
8-[(naphth-2-yl-methyl)]-1-phenyl-2,3,8-triazospiro[4.5]decan-4-one;
8-(*p*-phenylbenzyl)-1-phenyl-2,3,8-triazospiro[4.5]decan-4-one;
8-[4,4-Bis(4-fluorophenyl)butyl]-1-phenyl-2,3,8-triazospiro[4.5]decan-4-one;
8-(benzyl)-1-phenyl-2,3,8-triazospiro[4.5]decan-4-one;
8-(10,11-Dihydro-5H-dibenzo[a,d]-cyclohepten-5-yl)-1-phenyl-2,3,8-triazospiro[4.5]decan-4-one;
8-(3,3-Bis(phenyl)propyl)-1-phenyl-2,3,8-triazospiro[4.5]decan-4-one;
8-(*p*-benzyloxybenzyl)-1-phenyl-2,3,8-triazospiro[4.5]decan-4-one;
8-(cyclooctylmethyl)-1-phenyl-2,3,8-triazospiro[4.5]decan-4-one; and
pharmaceutically acceptable salts thereof.

18. A compound which is 8-(acenaphthen-9-yl)-1-phenyl-2,3,8- triazospiro[4.5]decan-4-one or a pharmaceutically acceptable salt thereof or solvate thereof.

19. A pharmaceutical composition comprising a compound of claim 1 and at least one pharmaceutically acceptable excipient.

20. A method of treating pain comprising administering to a patient in need thereof, an effective amount of an analgesic compound according to claim 1.

21. A method of modulating a pharmacological response from the ORL1 receptor comprising administering to a patient in need thereof an effective amount of a compound according to claim 1.

22. A pharmaceutical composition comprising a compound of claim 7 and at least one pharmaceutically acceptable excipient.

23. A method of treating pain comprising administering to a patient in need thereof, an effective amount of an analgesic compound according to claim 7.

24. A method of modulating a pharmacological response from the ORL1 receptor comprising administering an effective amount of a compound according to claim 7.

25. A compound of formula (IA):



(IA)

wherein

R_2 is selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{3-12} cycloalkyl and halogen; said alkyl optionally substituted with an oxo group;

n is an integer from 0 to 3;

and ZR_1 is



wherein

Y_1 is R_3-(C_1-C_{12})alkyl, R_4-aryl, R_5-heteroaryl, R_6-(C_3-C_{12})cyclo-alkyl, R_7-(C_3-C_7)heterocycloalkyl, -CO_2(C_1-C_6)alkyl, CN or -C(O)NR_8R_9; Y_2 is hydrogen or Y_1; Y_3 is hydrogen or (C_1-C_6)alkyl; or Y_1, Y_2 and Y_3, together with the carbon to which they are attached, form one of the following structures:







or

wherein r is 0 to 3; w and u are each 0-3, provided that the sum of w and u is 1-3; c and d are independently 1 or 2; s is 1 to 5; and ring E is a fused R_4-phenyl or R_5-heteroaryl ring;

R_{10} is 1 to 3 substituents independently selected from the group consisting of H, (C_1-C_6)alkyl, -OR_8, - (C_1-C_6)alkyl-OR_8, -NR_8R_9 and -(C_1-C_6)alkyl-NR_8R_9;

R_{11} is 1 to 3 substituents independently selected from the group consisting of R_{10}, -CF_3, -OCF_3, NO_2 and halo, or R_{11} substituents on adjacent ring carbon atoms may together form a methylenedioxy or ethylenedioxy ring;

R_8 and R_9 are independently selected from the group consisting of hydrogen, (C_1-C_6) alkyl, (C_3-C_{12})cycloalkyl, aryl and aryl(C_1-C_6)alkyl;

R_3 is 1 to 3 substituents independently selected from the group consisting of H, R_4-aryl, R_6-(C_3-C_{12})cycloalkyl, R_5-heteroaryl, R_7-(C_3-C_7)heterocycloalkyl, -NR_8 R_9, -OR_{12} and -

$S(O)_{0-2}R_{12}$;

R_6 is 1 to 3 substituents independently selected from the group consisting of H, (C_1-C_6)alkyl, R_4-aryl, -NR_8R_9 , -OR_{12} and -SR_{12};

R_4 is 1 to 3 substituents independently selected from the group consisting of hydrogen, halo, (C_1- C_6)alkyl, R_{13}-aryl, (C_3 - C_{12})cycloalkyl, -CN, -CF_3, -OR_8, -(C_1-C_6)alkyl-OR_8, -OCF_3, -NR_8R_9, -(C_1 - C_6)alkyl -NR_8R_9, -$NHSO_2R_8$, -$SO_2N(R_{14})_2$, -SO_2R_8, -SOR_8, -SR_8, -NO_2, -$CONR_8R_9$, -NR_9COR_8, -COR_8, -$COCF_3$, -$OCOR_8$, -OCO_2R_8, -$COOR_8$, -(C_1-C_6)alkyl-$NHCOOC(CH_3)_3$, -(C_1-C_6)alkyl-$NHCOCF_3$, -(C_1-C_6)alkyl-$NHSO_2$-(C_1-C_6)alkyl, -(C_1-C_6)alkyl-NHCONH-(C_1-C_6)-alkyl and



wherein f is 0 to 6; or R_4 substituents on adjacent ring carbon atoms may together form a methylenedioxy or ethylenedioxy ring;

R_5 is 1 to 3 substituents independently selected from the group consisting of hydrogen, halo, (C_1-C_6)alkyl, R_{13}-aryl, (C_3-C_{12})cycloalkyl, -CN, -CF_3, -OR_8, -(C_1-C_6)alkyl-OR_8, -OCF_3,-NR_8R_9, -(C_1-C_6)alkyl-NR_8R_9, -$NHSO_2R_8$, -$SO_2N(R_{14})_2$, -NO_2, -$CONR_8R_9$, -NR_9COR_8, -COR_8, -$OCOR_8$, -OCO_2R_8 and -$COOR_8$;

R_7 is H, (C_1-C_6)alkyl, -OR_8, -(C_1-C_6)alkyl-OR_8, -NR_8R_9 or -(C_1-C_6)alkyl-NR_8R_9;

R_{12} is H, (C_1-C_6)alkyl, R_4-aryl, -(C_1-C_6)alkyl-OR_8, -(C_1-C_6)alkyl-NR_8R_9, -(C_1-C_6)alkyl-SR_8, or aryl (C_1-C_6)alkyl;

R_{13} is 1-3 substituents independently selected from the group consisting of H, (C_1-C_6)alkyl, (C_1-C_6)alkoxy and halo;

R_{14} is independently selected from the group consisting of H, (C_1-C_6)alkyl and R_{13}-C_6H_4-CH_2-;

or a pharmaceutically acceptable salt thereof.

26. A pharmaceutical composition comprising a compound of claim 25 and at least one pharmaceutically acceptable excipient.

27. A method of treating pain comprising administering to a patient in need thereof, an effective amount of an analgesic compound according to claim 25.

28. A method of modulating a pharmacological response from the ORL1 receptor comprising administering to a patient in need thereof, an effective amount of a compound according to claim 25.

29. A method of modulating a pharmacological response from an opioid receptor comprising administering to a patient in need thereof, an effective amount of a compound according to claim 1.

30. A method of modulating a pharmacological response from an opioid receptor comprising administering to a patient in need thereof, an effective amount of a compound according to claim 7.

31. A method of modulating a pharmacological response from an opioid receptor comprising administering to a patient in need thereof, an effective amount of a compound according to claim 25.